Hidden Superbug Built Resistance in Waves, Peaking in Mid-2000s

A study published in the journal *Nature Microbiology* has revealed that a hospital-acquired superbug, *Acinetobacter baumannii*, developed antibiotic resistance in distinct waves, with the most significant increase in resistance occurring between 2005 and 2007, according to a team of researchers from the University of Cambridge and the Wellcome Sanger Institute. The findings, based on genomic analysis of bacterial samples collected over six decades, challenge previous assumptions about the timeline and mechanisms of antimicrobial resistance development in clinical settings.

The research team analyzed 1,200 isolates of *A. baumannii* from hospital outbreaks across Europe, the United States, and Asia, dating from 1960 to 2020. By mapping genetic mutations linked to resistance, the scientists identified three distinct phases of resistance spread. The first wave, from the 1960s to the early 1990s, involved resistance to older antibiotics like tetracycline and sulphonamides. The second wave, from the mid-1990s to the early 2000s, saw the emergence of resistance to broader-spectrum drugs, including cephalosporins. The third and most severe wave, peaking between 2005 and 2007, coincided with the rise of carbapenem resistance, a class of last-resort antibiotics.

“This study shows that resistance doesn’t occur in a single burst but builds up through multiple, overlapping waves,” said Dr. Emily Carter, a microbiologist at the University of Cambridge and co-lead author of the study. “The mid-2000s peak aligns with increased global travel and the widespread use of carbapenems in intensive care units, which likely accelerated the spread of resistant strains.”

The research also uncovered that the superbug’s resistance was driven by horizontal gene transfer, where bacteria share genetic material through plasmids and transposons. This mechanism allowed *A. baumannii* to acquire multiple resistance genes rapidly, making it difficult to treat with existing antibiotics. The study highlights how the overuse and misuse of antibiotics in healthcare settings created selective pressure for these resistant strains to dominate.

Health officials have long warned about the dangers of antibiotic resistance, but the study provides a granular timeline that could inform future infection control strategies. The World Health Organization (WHO) cited the findings in a 2026 report on global antimicrobial resistance, emphasizing the need for stricter antibiotic stewardship programs and improved hospital hygiene protocols.

Comparisons with earlier studies on *A. baumannii* show a similar pattern of resistance development. A 2015 analysis by the Centers for Disease Control and Prevention (CDC) noted a 30% increase in carbapenem-resistant cases between 2000 and 2010, aligning with the mid-2000s peak identified in the new study. However, the Cambridge-led research offers a more detailed genetic framework, which could aid in the development of targeted therapies and diagnostic tools.

The implications of the study extend beyond *A. baumannii*. Researchers are now applying the same genomic analysis techniques to other hospital-acquired pathogens, such as *Pseudomonas aeruginosa* and *E. coli*. Dr. Carter explained that understanding resistance waves could help predict future threats. “If we can anticipate how resistance will evolve, we can develop drugs and policies that stay ahead of the curve,” she said.

Despite the findings, challenges remain in combating antibiotic-resistant bacteria. The study notes that new antibiotics have been slow to reach the market, with only two novel classes approved since 2010. Meanwhile, the global pipeline for antimicrobial drugs is described as “alarmingly sparse” by the WHO, raising concerns about a potential post-antibiotic era.

In response to the research, the European Centre for Disease Prevention and Control (ECDC) has called for increased funding for antimicrobial resistance surveillance. A